Tech Company Financing Transactions

Presidio Pharmaceuticals Funding Round

Presidio Pharmaceuticals secured a $27 million Series B funding round on 7/10/2009. Investors included Baker Brothers Investments, Bay City Capital and New Leaf Venture Partners.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

1700 Owens St. 184
San Francisco, CA 94158
USA

Phone

(415) 655-7560

Website

www.presidiopharma.com

Email Address

[email protected]

Overview

Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Financial Officer

Leo Redmond

        

Chief Medical Officer

Nathaniel Brown

        

Chief Scientific Officer

Richard Colonno

        

VP - Regulatory Affairs

Eric Ruby

        

Browse more venture capital transactions:

Prev: 7/10/2009: GumGum venture capital transaction
Next: 7/10/2009: Telligent venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary